卡门伯特奶酪中存在的脂肪酸胺基在小鼠口服后改善了认知衰退
Kohei Kawano1, Maiko Shobako1, Taichi Furukawa1
1Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Japan.
Neuroscience research
|March 8, 2024
概括
卡曼伯特奶酪 (CC) 和它的脂肪酸胺,米里斯塔胺 (MA),改善了小鼠的认知衰退. 脂肪酸化似乎对这种对记忆和脑源性神经营养因子表达的有益影响至关重要.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 生物化学 生化学
背景情况:
- 认知能力下降是一个越来越令人担忧的问题,通常由高脂肪饮食加剧.
- 饮食成分,例如发酵食品中的成分,可能会提供保护作用.
- 脂肪酸胺是食品发酵过程中产生的生物活性化合物.
研究的目的:
- 调查卡门伯特奶酪 (CC) 和其脂肪酸胺基对小鼠认知功能的影响.
- 为了确定脂肪酸化是否对观察到的认知益处至关重要.
- 探索分子机制,特别是海马体中神经生成相关基因表达的变化.
主要方法:
- 对象识别测试用于评估小鼠海马依赖记忆.
- 卡门伯特奶酪和特定脂肪酸胺基 (米里斯塔胺,胺,胺) 的口服.
- 与非胺基脂肪酸 (米里斯酸) 的比较.
- 在海马体中对神经发生标记物的mRNA表达分析.
主要成果:
- 口服卡门伯特奶酪改善了由高脂肪饮食引起的认知衰退.
- 米里斯塔胺 (MA) 显著改善了认知功能,而米里斯酸没有.
- 麻醉剂的使用导致海马体脑源性神经营养因子 (BDNF) mRNA表达的增加.
结论:
- 香奶酪及其成分米里斯塔胺显示有提高认知功能的潜力.
- 脂肪酸化似乎是这些化合物的生物活性的一个关键因素.
- 米里斯塔米德可能通过增强神经发生相关途径来发挥其作用,特别是增加海马中的BDNF表达.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481


